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Cervical dystonia (CD) is a movement disorder which affects daily living of many patients. 
In clinical practice, several unmet treatment needs remain open. This article focuses 
on the four main aspects of treatment. We describe existing and emerging treatment 
approaches for CD, including botulinum toxin injections, surgical therapy, management 
of non-motor symptoms, and rehabilitation strategies. The unsolved issues regarding 
each of these treatments are identified and discussed, and possible future approaches 
and research lines are proposed.
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iNtrODUctiON
Cervical dystonia (CD) is the most prevalent form of adult-onset focal dystonia, and is characterized 
by abnormal postures of head and neck, that can considerably impair daily living.
There are several unmet needs in the management of CD. In this article, we focused on four main 
aspects of the treatment of this disorder, including botulinum toxin injections, surgical therapy, 
management of non-motor symptoms (NMS), and rehabilitation strategies.
For each of these issues the state-of-the art is presented and some of the current knowledge gaps 
are highlighted. In addition, we propose potential research lines that could be developed to manage 
these issues.
BOtULiNUM tOXiN
What is Known?
Botulinum neurotoxin (BoNT) injections are the treatment of choice for CD.
There is class I evidence to support efficacy and safety of the three commercially available formu-
lations of BoNT-A (onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA) (1–3), 
and of BoNT-B (rimabotulinumtoxin B) (4).
As much as 70–85% of the patients report a significant benefit from the treatment (5). Efficacy on 
motor symptoms varies from 20 to 70%, based on the assessing method used. Significant improve-
ment is also documented on pain and quality of life (QoL) (6).
Although BoNT treatment is routinely performed worldwide and is satisfying for many patients, 
the obtained effect is still far from optimal. In addition, BoNT treatment is in some cases associated 
with the occurrence of side effects, such as dysphagia or excessive muscle weakness. These side effects 
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are due to an excessive dose of BoNT or to the spread of BoNT to 
adjacent structures, and may limit the efficacy of the treatment.
What is Uncertain?
In order to further improve the efficacy and safety of the treat-
ment, the accurate placement of the minimum effective dose of 
toxin in the dystonic muscles should be ensured. At present, there 
is still no agreement on a recommended starting dose or on the 
minimum effective dose per muscle.
Moreover, there is still great variability concerning treatment 
strategies. Multi-point BoNT injections have been proposed as 
more effective than single point injections (7), but convincing 
evidence on these topics is still lacking.
The use of polymyography to identify dystonic muscles before 
treatment, and the use of electromyography (EMG) to guide 
injections, has been proposed to improve the accuracy of BoNT 
delivery. While some studies show that this approach may pro-
vide a significant advantage in BoNT-naïve patients (8, 9), as well 
as in patients unsatisfactorily treated with standard injections 
(10, 11), this still need to be further confirmed in larger series. 
Moreover, the modalities and indications of the neurophysiologi-
cal approach need to be further specified.
The use of imaging techniques has also been proposed to 
identify the dystonic muscles before treatment and to improve the 
accuracy of the placement of BoNT. Preliminary reports suggest 
that the use of ultrasound-guided injections might help localizing 
the target muscles and reducing the episodes of dysphagia in 
patients who had experienced it with standard treatment (12).
A number of patients do not respond to BoNT treatment, or 
develop a secondary resistance. A currently accepted definition of 
secondary non-responsiveness implies “insufficiently improved 
posture after three or more unsuccessful injection cycles in CD 
patient’s previously achieving satisfactory results” (13).
Change in CD pattern across time, with the appearance of 
more complex multiaxial dystonic movements or tremor, account 
for some of the non-responders. Another well-known cause of 
non-responsiveness is the development of antibodies against 
BoNT formulations (14). This issue has been described with 
different BoNT formulations, including onabotulinumtoxinA, 
abobotulinumtoxinA, and rimabotulinumtoxinB (15), while it 
does not seem to be a concern when incobotulinumtoxinA is 
used (16). At present, there is no agreement on the strategies to 
avoid the formation of antibodies. Although this problem likely 
occurs only sporadically, a minimum safe interval of 12 weeks or 
longer is still used in most centers (17). This strategy, however, 
limits treatment of a larger number of patients, who report 
reemergence of symptoms before this time. The safety of shorter 
intervals between injections and of the so-called booster injec-
tions still needs to be explored.
Another unsolved and largely debated practical issue concerns 
the optimal conversion ratio between different formulation of 
BoNT-A, or between BoNT-A and BoNT-B.
Based on studies using different methodology, a conversion of 
onabotulinumtoxinA to abobotulinumtoxinA 1:3 IU (18, 19), as 
well as ratios of 1:2.5 (20) have been proposed over time, while 
a conversion ratio of 1:1 is proposed for onabotulinumtoxinA to 
incobotulinumtoxinA.
Future Perspectives
Future research lines should focus on improving the benefit/
side effects ratio of BoNT treatment and on reducing the rate of 
primary and secondary non-responsive patients.
A standardized working definition of non-responsiveness 
should be developed, which should take into account an objective 
measure of the lack of improvement as well as an evaluation of the 
appropriateness of BoNT treatment. An objective and universally 
accepted working definition would be of crucial importance to 
assess new treatment strategies and to identify patients for whom 
more invasive (surgical) treatment are indicated.
Dose-finding studies and comparative studies across different 
toxins should be performed. The additional value of neurophysi-
ology and imaging in improving the intramuscular placing of 
BoNT should be explored. In order to minimize patients’ dis-
comfort, the minimum safe interval between treatments should 
be determined.
sUrGicAL treAtMeNt
What is Known?
Deep brain stimulation (DBS) of the internal globus pallidus 
(GPi) is an established surgical treatment for patients with gen-
eralized dystonia (21, 22). Because the initial studies suggested 
an equally beneficial effect for all body regions, the method was 
soon applied to patients with focal or segmental dystonias, who 
no longer responded to BoNT.
Krauss was the first to describe the beneficial outcome in three 
patients with CD in 1999 (23). Meanwhile three controlled clini-
cal studies were conducted evaluating GPi-DBS in CD patients 
who failed on medical treatment: a Canadian prospective, 
multicenter and observer-blinded study assessed 10 CD patients 
who were further followed for 12 months (24). Motor improve-
ment was 28% at 6  months and 43% at 12  months (TWSTRS 
motor score). Pain and disability scores were also improved 
by 66 and 64%, as well as mood [Beck’s Depression Inventory 
(BDI)] and QoL (SF-36) by 58 and 24%, respectively. Another 
prospective single-center study followed eight CD patients for 
up to 48 months after GPi-DBS (25), reporting a median reduc-
tion in the TWSTRS motor score of 50% at 6  months and of 
73% at last follow-up. The only randomized sham-controlled 
multicenter study of bilateral GPi-DBS in CD followed patients 
for a total of 6–9 months after surgery (26). Sixty-two patients 
were implanted with a neurostimulation system and randomly 
assigned to either active or sham stimulation (stimulator output 
0V). After 3  months, TWSTRS severity score was reduced by 
26% in the treatment group compared to 6% in the sham group. 
There was a 3.8 point difference between both groups, which 
was significant. TWSTRS disability score and Bain tremor score 
were also significantly improved in the neurostimulation group, 
whereas TWSTRS pain score and QoL (Craniocervical Dystonia 
Questionnaire-24 score) were not different. Evaluations were 
repeated in all patients after receiving 6  months of effective 
neurostimulation. At the follow-up, significant improvements 
compared to the pre-surgical baseline were found for TWSTRS 
severity score (28%), disability score (46%) and pain (51%), 
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Tsui score (57%), Bain tremor score (66%), and global dystonia 
ratings by patients (49%) or physicians (53%). BDI was reduced 
by 20%, the cranio-cervical dystonia questionnaire-24 showed 
a 28% improvement. No permanent adverse effects were found. 
Transient adverse effects included device infection (n = 3), mis-
placement/dislocation of electrodes (n = 3) or neurostimulator 
(n = 1), stroke/hemorrhage (n = 1), and seizure (n = 1). Four 
patients claimed pain at the extension cable. The most frequent 
stimulation-induced side-effect was dysarthria (seven patients). 
Stimulation-induced bradykinesia was observed in one patient, 
but has previously been described as a relevant adverse effect of 
pallidal neurostimulation in several series (27, 28).
It has been suggested that the subthalamic nucleus could be a 
better target for DBS in CD with equal motor benefit but less risk 
of stimulation-induced parkinsonism (29).
What is Uncertain?
Larger series are needed to ascertain which types of CD respond 
best to pallidal DBS, and to assess predisposing factors and the 
true prevalence and risk factors of stimulation-induced parkin-
sonism. Subthalamic stimulation, which was forwarded as an 
alternative, induces (transient) dyskinesia in a large proportion 
of patients and the cognitive and behavioral safety has not been 
evaluated yet. So far, DBS has been advocated only in patients no 
longer responding to BoNT treatment, as a last line therapy. A 
comparative trial of BoNT treatment in comparison to DBS has 
not been performed yet.
Future Perspectives
Registry data of DBS surgery in CD would help to evaluate 
outcomes in daily practice, define responder profiles, and assess 
the frequency of less common adverse effects. The effect of 
DBS on non-motor features should be systematically assessed. 
Randomized controlled trials (RCTs) are needed to compare 
pallidal and subthalamic neurostimulation and DBS in general 
vs. best conservative management of CD.
MANAGeMeNt OF NON-MOtOr 
sYMPtOMs
What is Known?
Growing evidence suggests that the phenotype of dystonia 
includes also NMS, which could in part account for the reduced 
QoL in CD (30, 31).
Sensory abnormalities are the most frequently NMS associ-
ated with CD. The onset of motor symptoms can be preceded 
by a feeling of discomfort in the neck and dystonic movements 
are sometimes interpreted as an attempt to decrease this feel-
ing (32). Involvement of the sensory system is also indicated by 
the geste antagoniste, which modifies cortical EEG activity and 
GPi local field potentials, even before touching the head (33). 
Furthermore, several studies found abnormalities in temporal 
and spatial discrimination thresholds in CD patients, both in 
affected and unaffected body parts, and in unaffected first-degree 
relatives (34, 35).
Pain is present in up to 90% of CD patients, which is rated 
as moderate to severe by 70% (36). Two-third of the patients 
use analgesics. Pain might be a consequence of motor symptom 
severity (37), but could also be influenced by depressive and 
anxiety symptoms (31). It is proven that BoNT treatment as well 
as surgical treatments, such as DBS (26) or selective peripheral 
denervation (38), significantly improves pain associated with 
CD (36, 37).
The prevalence of psychiatric disorders in CD can reach up 
to 91.4%, compared to 35% in the general population (39). This 
could logically be the consequence of living with a chronic, 
visible, and invalidating disorder. However, compared to the 
prevalence of psychiatric symptoms in other chronic and visible 
diseases, such as alopecia areata, CD patients still have a signifi-
cantly increased odds ratio to develop psychiatric co-morbidity 
(40). The most prevalent psychiatric disorders include depressive 
symptoms (40–45), anxiety symptoms/panic disorders (39, 40, 
44, 45), obsessive–compulsive symptoms (41, 45) and substance 
abuse (45). Importantly, a few studies showed that psychiatric co-
morbidity is the most important predictor of poorer health-related 
QoL, especially for the domains general health, role functioning, 
bodily pain, and emotional and mental health (31, 46, 47).
At this moment, no treatment trials have been described with 
the aim to directly improve psychiatric symptoms in CD patients.
What is Uncertain?
The prevalence and characteristics of the different NMS in CD, 
including sleep disturbances and cognition, have not been sys-
tematically studied and existing studies show contrasting results. 
A recurring debate is whether NMS are a direct consequence of 
the motor symptoms of dystonia or intrinsic to the neurobiology 
and thereby part of the phenotype.
Cervical dystonia patients showed an impaired sleep quality 
compared to healthy controls: in two studies, this was correlated 
with depressive symptom scores (48, 49), while in one study it 
appeared to be independent from psychiatric disorders and 
medication use (50). Successful BoNT treatment did not improve 
sleep quality, arguing against a secondary discomfort due to the 
dystonia motor symptoms (50). Excessive daytime sleepiness was 
detected in one study, but at least in part explained by the use of 
anticholinergic drugs (51). Other studies did not find significant 
differences in daytime sleepiness (48, 49).
Studies concerning cognitive impairment in CD are still very 
limited. One study showed impairments in the domains working 
memory, processing speed, visual motor ability, and short-term 
memory (52). Other small studies found impairment of visuos-
patial function (53) and a sustained attention deficit, the latter 
disappearing after BoNT treatment (54).
Convincing data support a disruption of sensory-motor 
system also in healthy first-degree relatives of dystonic patients, 
suggesting a possible endophenotype (55). For example, temporal 
discrimination threshold (TDT) was found abnormal not only 
in about 80% of dystonia patients but also in about 50% of 
first-degree female relatives older than 48. In male relatives, the 
penetrance was reduced (34, 56).
The onset of psychiatric disorders before the onset of the 
movement disorder in ~70% of the cases (42, 44, 45) is one of 
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the strongest arguments toward a shared pathophysiology. This is 
also supported by a men-to-women ratio of psychiatric disorders 
of 1:1 in CD patients compared to 1:2 in the general popula-
tion, higher incidence of psychiatric disorders in CD patients 
compared to other visible and chronic disorders, and different 
personality profiles found in CD patients, which develop long 
before adolescence and onset of motor symptoms (35).
Drawing firm conclusions on the etiology of NMS in CD 
remains difficult, also considering the tight correlation between 
pain, psychiatric symptoms, sleep disturbances, and motor 
symptoms.
Future Perspectives
In order to solve the issue of the etiology of NMS in CD, pro-
spective studies are necessary. Selecting an appropriate group 
for prospective studies has proven challenging. This might 
change with the identification of genetic forms of CD, such as 
the GNAL and ANO3 gene (57–60), which would allow studying 
homogeneous clinical subgroups, even in the pre-symptomatic 
phase.
Another strategy could be the identification of endopheno-
types in larger groups, based on biomarker, such as the TDT.
Clinical trials are required toward the effect of treatment of 
NMS on health-related QoL.
reHABiLitAtiON strAteGies
What is Known?
Evidence toward the effectiveness of rehabilitation strategies is 
scarce. Two systematic reviews described the effects of different 
rehabilitation strategies in various forms of primary dystonia (61) 
and CD alone (62), suggesting that multimodal physical therapy 
(PT) programs, added to BoNT treatment, further improve 
disability and pain compared to BoNT treatment alone (61, 62). 
Only three clinical trials (63–65) and one case–control study (66) 
investigated the effects of a multimodal PT program in combina-
tion with BoNT treatment.
One single-blind RCT in 40 patients showed significant 
improvements on pain and daily-life activities, and a prolonged 
duration of the BoNT effect, after a 6-week PT program of active 
exercises, muscle stretching and massage compared to BoNT 
treatment alone (63). A second single-blind RCT in 40 patients 
showed decreased disability and a significant decrease of head 
deviation and improved hand functions after a 6-week PT pro-
gram of active exercise, muscle stretching, and TENS in addition 
to BoNT treatment (64). The third single-blind RCT of 20 patients 
found only a trend toward greater improvement on head posture, 
pain, and disability in the group that received 12 weeks of active 
exercise, relaxation, and BoNT treatment compared to the group 
that received relaxation and BoNT treatment only (65).
One case–control study followed 40 patients in a 4-week PT 
program of active exercise, muscle stretching, active and passive 
neck mobilizations, and electrostimulation of the dystonic mus-
cles in adjunction to BoNT treatment, or BoNT treatment alone. 
The PT group showed significantly more improvement on pain, 
and on some subscales of the SF-36 (66).
What is Uncertain?
The available results should be interpreted with caution. The 
content of PT programs varied across studies, including motor 
learning exercises [Bleton method (67)], passive or active 
mobilization techniques of the cervical spine, stretching of the 
dystonic muscles, relaxation, and electrotherapy, such as EMG 
biofeedback or TENS. It is, therefore, difficult to identify the most 
effective intervention or combination of interventions.
Frequency and duration of PT sessions also varied from 40 min 
every other day for 6 weeks (64), 75 min 5 days a week for 5 weeks 
(66), 90 min a day for 2 weeks (63) up to a 12-week program with 
a weekly 30-min session during the first 4-weeks, and a session 
every fortnight for the remaining 8 weeks (65). Besides, current 
studies mainly show short-term effects associated with brief and 
intensive PT programs (63, 64, 66), which could be difficult to 
implement in current regular care of a chronic disease, such as 
CD. The long-term effects of less intense and longer PT programs 
have not been explored yet.
Future Perspectives
Future research should focus on standardized PT programs that 
are effective but also adequate to treat patients with a chronic 
conditions and an active life. PT programs with longer treatment 
periods and the emphasis on self-management of symptoms and 
the ability of patients to improve their performance of daily life 
tasks should be the focus. Currently, such a PT program is being 
investigated in a large Dutch RCT (68).
The effect of PT interventions on the pathophysiological 
mechanisms of CD should also be studied. Although the patho-
physiology of CD remains largely unclear, maladaptive neuro-
plastic changes may play an important role (69). By integrating 
PT programs with modern training principles that have proven 
relevant for neural rehabilitation and motor learning, these deficit 
may be altered (70–74).
Additionally, high-quality research combining electrophysi-
ological parameters or imaging techniques with clinical outcomes 
can help to further unravel the effects of PT programs on CD.
FiNAL cONsiDerAtiONs
There are still many unmet needs in the management of CD. A 
better understanding of the pathophysiology of CD is necessary 
to plan new treatment strategies and to improve existing treat-
ments. In addition, the available rating scales for CD have some 
clinimetric issues and do not equally address all the domains of 
the disease. This points to a need for updated scoring instruments 
in order to support studies on the pathogenesis and progression 
of the disease and to more accurately evaluate the outcomes 
of clinical trials. Specific standardized rating scale for NMS in 
(cervical) dystonia should also be developed.
Finally, it is widely accepted that motor improvement is not 
the only determinant of treatment success in CD: pain, social 
distress, and psychological factors play sometimes a greater role 
toward patient satisfaction. This calls for a multi-disciplinary 
approach posing more attention to the subjective determinants 
of QoL in CD.
5Contarino et al. Unmet Needs in the Management of Cervical Dystonia
Frontiers in Neurology | www.frontiersin.org September 2016 | Volume 7 | Article 165
AUtHOr cONtriBUtiONs
All the authors (MC, MS, JD, JV, and MT) provided substantial 
contributions to the conception or design of the work; drafted 
part of the manuscript and revised the rest of the manuscript 
critically for important intellectual content; approved the final 
version to be published; agreed to be accountable for all aspects 
of the work.
reFereNces
1. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, et al. What is 
the optimal dose of botulinum toxin A in the treatment of cervical dystonia? 
Results of a double blind, placebo controlled, dose ranging study using 
Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 
(1998) 64:13–7. doi:10.1136/jnnp.64.1.13 
2. Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF, et al. Efficacy, 
tolerability, and immunogenicity of onabotulinumtoxina in a random-
ized,  double-blind, placebo-controlled trial for cervical dystonia. Clin 
Neuropharmacol (2012) 35:208–14. doi:10.1097/WNF.0b013e31826538c7 
3. Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, U.S. XEOMIN 
Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA 
(NT 201, XEOMIN(R), botulinum neurotoxin type A, without accessory 
proteins) in patients with cervical dystonia. J Neurol Sci (2011) 308:103–9. 
doi:10.1016/j.jns.2011.05.041 
4. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, 
et  al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type 
A-responsive cervical dystonia. Neurology (1999) 53:1439–46. doi:10.1212/
WNL.53.7.1439 
5. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, et al. 
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: 
results of the first US randomized, double-blind, placebo-controlled study. 
Mov Disord (2005) 20:783–91. doi:10.1002/mds.20403 
6. Mordin M, Masaquel C, Abbott C, Copley-Merriman C. Factors affecting the 
health-related quality of life of patients with cervical dystonia and impact of 
treatment with abobotulinumtoxinA (Dysport): results from a randomised, 
double-blind, placebo-controlled study. BMJ Open (2014) 4:e005150. 
doi:10.1136/bmjopen-2014-005150 
7. Borodic GE, Pearce LB, Smith K, Joseph M. Botulinum a toxin for spasmodic 
torticollis: multiple vs single injection points per muscle. Head Neck (1992) 
14:33–7. doi:10.1002/hed.2880140108 
8. Werdelin L, Dalager T, Fuglsang-Frederiksen A, Regeur L, Karlsborg M, 
Korbo L, et al. The utility of EMG interference pattern analysis in botulinum 
toxin treatment of torticollis: a randomised, controlled and blinded study. 
Neurophysiol Clin (2011) 122:2305–9. doi:10.1016/j.clinph.2011.04.012 
9. Comella CL, Buchman AS, Tanner CM, Browntoms NC, Goetz CG. 
Botulinum toxin injection for spasmodic torticollis – increased magnitude 
of benefit with electromyographic assistance. Neurology (1992) 42:878–82. 
doi:10.1212/WNL.42.4.878 
10. Nijmeijer SWR, Koelman JHTM, Standaar TSM, Postma M, Tijssen  MAJ. 
Cervical dystonia: improved treatment response to botulinum toxin after 
referral to a tertiary centre and the use of polymyography. Parkinsonism Relat 
Disord (2013) 19:533–8. doi:10.1016/j.parkreldis.2013.01.018 
11. Cordivari C, Misra VP, Vincent A, Catania S, Bhatia KP, Lees AJ. Secondary 
nonresponsiveness to botulinum toxin a in cervical dystonia: the role of 
electromyogram-guided injections, botulinum toxin a antibody assay, and the 
extensor digitorum brevis test. Mov Disord (2006) 21:1737–41. doi:10.1002/
mds.21051 
12. Hong JS, Sathe GG, Niyonkuru C, Munin MC. Elimination of dysphagia 
using ultrasound guidance for botulinum toxin injections in cervical dystonia. 
Muscle Nerve (2012) 46:535–9. doi:10.1002/mus.23409 
13. Ferreira JJ, Colosimo C, Bhidayasiri R, Marti MJ, Maisonobe P, Om S. Factors 
influencing secondary non-response to botulinum toxin type A injections in 
cervical dystonia. Parkinsonism Relat Disord (2015) 21:111–5. doi:10.1016/ 
j.parkreldis.2014.09.034 
14. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin 
type A in patients with torticollis. Mov Disord (1994) 9:213–7. doi:10.1002/
mds.870090216 
15. Kessler KR, Skutta M, Benecke R. Long-term treatment of cervical dystonia 
with botulinum toxin A: efficacy, safety, and antibody frequency. German 
Dystonia Study Group. J Neurol (1999) 246:265–74. 
16. Dressler D, Tacik P, Adib Saberi F. Botulinum toxin therapy of cervical dysto-
nia: comparing onabotulinumtoxinA (Botox((R))) and incobotulinumtoxinA 
(Xeomin ((R))). J Neural Transm (Vienna) (2014) 121:29–31. doi:10.1007/
s00702-013-1076-z 
17. Novak I, Campbell L, Boyce M, Fung VS, Cerebral Palsy Institute. Botulinum 
toxin assessment, intervention and aftercare for cervical dystonia and 
other causes of hypertonia of the neck: international consensus statement. 
Eur J Neurol (2010) 17(Suppl 2):94–108. doi:10.1111/j.1468-1331.2010. 
03130.x 
18. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al.  
A double blind, randomised, parallel group study to investigate the dose 
equivalence of Dysport and Botox in the treatment of cervical dystonia. 
J Neurol Neurosurg Psychiatry (1998) 64:6–12. doi:10.1136/jnnp.64.1.6 
19. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of 
Botox and Dysport: a double blind, randomised, crossover study in cervical 
dystonia. J Neurol Neurosurg Psychiatry (2002) 72:459–62. 
20. Yun JY, Kim JW, Kim HT, Chung SJ, Kim JM, Cho JW, et al. Dysport and Botox 
at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study. 
Mov Disord (2015) 30:206–13. doi:10.1002/mds.26085 
21. Vidailhet M, Vercueil L, Houeto JL, Krystkowiak P, Benabid AL, Cornu P, 
et al. Bilateral deep-brain stimulation of the globus pallidus in primary gen-
eralized dystonia. N. Engl. J. Med (2005) 352:459–67. doi:10.1056/NEJMoa 
042187 
22. Kupsch A, Benecke R, Mueller J, Trottenberg T, Schneider G-H, Poewe W, 
et  al. Pallidal deep-brain stimulation in primary generalized or segmental 
dystonia. New Engl J Med (2006) 355:1978–90. doi:10.1056/NEJMoa 
063618 
23. Krauss JK, Pohle T, Weber S, Ozdoba C, Burgunder JM. Bilateral stimulation 
of globus pallidus internus for treatment of cervical dystonia. Lancet (1999) 
354:837–8. doi:10.1016/S0140-6736(99)03084-6 
24. Kiss ZHT, Doig-Beyaert K, Eliasziw M, Tsui J, Haffenden A, Suchowersky O, 
et al. The Canadian multicentre study of deep brain stimulation for cervical 
dystonia. Brain (2007) 130:2879–86. doi:10.1093/brain/awm229 
25. Skogseid IM, Ramm-Pettersen J, Volkmann J, Kerty E, Dietrichs E, 
Roste  GK. Good long-term efficacy of pallidal stimulation in cervical dys-
tonia: a prospective, observer-blinded study. Eur J Neurol (2012) 19:610–5. 
doi:10.1111/j.1468-1331.2011.03591.x 
26. Volkmann J, Mueller J, Deuschl G, Kuhn AA, Krauss JK, Poewe W, et  al. 
Pallidal neurostimulation in patients with medication-refractory cervical dys-
tonia: a randomised, sham-controlled trial. Lancet Neurol (2014) 13:875–84. 
doi:10.1016/S1474-4422(14)70143-7 
27. Schrader C, Capelle HH, Kinfe TM, Blahak C, Bazner H, Lutjens G, et al. GPi-
DBS may induce a hypokinetic gait disorder with freezing of gait in patients 
with dystonia. Neurology (2011) 77:483–8. doi:10.1212/WNL.0b013e3182 
27b19e 
28. Berman BD, Starr PA, Marks WJ Jr, Ostrem JL. Induction of bradykinesia 
with pallidal deep brain stimulation in patients with cranial-cervical dystonia. 
Stereotact Funct Neurosurg (2009) 87:37–44. doi:10.1159/000195718 
29. Ostrem JL, Racine CA, Glass GA, Grace JK, Volz MM, Heath SL, et  al. 
Subthalamic nucleus deep brain stimulation in primary cervical dystonia. 
Neurology (2011) 76:870–8. doi:10.1212/WNL.0b013e31820f2e4f 
30. Ben-Shlomo Y, Camfield L, Warner T, Grp EC. What are the determinants of 
quality of life in people with cervical dystonia? J Neurol Neurosurg Psychiatry 
(2002) 72:608–14. doi:10.1136/jnnp.72.5.608 
31. Pekmezovic T, Svetel M, Ivanovic N, Dragasevic N, Petrovic I, Tepavcevic DK, 
et  al. Quality of life in patients with focal dystonia. Clin Neurol Neurosurg 
(2009) 111:161–4. doi:10.1016/j.clineuro.2008.09.023 
32. Stamelou M, Edwards MJ, Hallett M, Bhatia KP. The non-motor syndrome of 
primary dystonia: clinical and pathophysiological implications. Brain (2012) 
135:1668–81. doi:10.1093/brain/awr224 
33. Tang JK, Mahant N, Cunic D, Chen R, Moro E, Lang AE, et al. Changes in 
cortical and pallidal oscillatory activity during the execution of a sensory trick 
6Contarino et al. Unmet Needs in the Management of Cervical Dystonia
Frontiers in Neurology | www.frontiersin.org September 2016 | Volume 7 | Article 165
in patients with cervical dystonia. Exp Neurol (2007) 204:845–8. doi:10.1016/ 
j.expneurol.2007.01.010 
34. Kimmich O, Molloy A, Whelan R, Williams L, Bradley D, Balsters J, et  al. 
Temporal discrimination, a cervical dystonia endophenotype: penetrance and 
functional correlates. Mov Disord (2014) 29:804–11. doi:10.1002/mds.25822 
35. Zurowski M, McDonald WM, Fox S, Marsh L. Psychiatric comorbidities in 
dystonia: emerging concepts. Mov Disord (2013) 28:914–20. doi:10.1002/
mds.25501 
36. Camargo CH, Cattai L, Teive HA. Pain relief in cervical dystonia with 
botulinum toxin treatment. Toxins (Basel) (2015) 7:2321–35. doi:10.3390/
toxins7062321 
37. Charles PD, Adler CH, Stacy M, Comella C, Jankovic J, Manack Adams 
A, et  al. Cervical dystonia and pain: characteristics and treatment patterns 
from CD PROBE (cervical dystonia patient registry for observation of 
onabotulinumtoxin A efficacy). J Neurol (2014) 261:1309–19. doi:10.1007/
s00415-014-7343-6 
38. Bergenheim AT, Nordh E, Larsson E, Hariz MI. Selective peripheral denerva-
tion for cervical dystonia: long-term follow-up. J Neurol Neurosurg Psychiatry 
(2015) 86:1307–13. doi:10.1136/jnnp-2014-307959 
39. Gundel H, Wolf A, Xidara V, Busch R, Ceballos-Baumann AO. Social phobia 
in spasmodic torticollis. J Neurol Neurosurg Psychiatry (2001) 71:499–504. 
doi:10.1136/jnnp.71.4.499 
40. Gundel H, Wolf A, Xidara V, Busch R, Ladwig KH, Jacobi F, et al. High psychi-
atric comorbidity in spasmodic torticollis: a controlled study. J Nerv Ment Dis 
(2003) 191:465–73. doi:10.1097/01.NMD.0000081667.02656.21 
41. Bihari K, Hill JL, Murphy DL. Obsessive-compulsive characteristics in patients 
with idiopathic spasmodic torticollis. Psychiatry Res (1992) 42:267–72. 
doi:10.1016/0165-1781(92)90118-M 
42. Fabbrini G, Berardelli I, Moretti G, Pasquini M, Bloise M, Colosimo C, et al. 
Psychiatric disorders in adult-onset focal dystonia: a case-control study. Mov 
Disord (2010) 25:459–65. doi:10.1002/mds.22983 
43. Jahanshahi M, Marsden CD. Depression in torticollis: a controlled study. 
Psychol Med (1988) 18:925–33. doi:10.1017/S0033291700009855 
44. Moraru E, Schnider P, Wimmer A, Wenzel T, Birner P, Griengl H, et  al. 
Relation between depression and anxiety in dystonic patients: implications 
for clinical management. Depress Anxiety (2002) 16:100–3. doi:10.1002/ 
da.10039 
45. Wenzel T, Schnider P, Wimmer A, Steinhoff N, Moraru E, Auff E. Psychiatric 
comorbidity in patients with spasmodic torticollis. J Psychosom Res (1998) 
44:687–90. doi:10.1016/S0022-3999(97)00229-8 
46. Ben-Shlomo Y, Camfield L, Warner T, ESDE Collaborative Group. What are 
the determinants of quality of life in people with cervical dystonia? J Neurol 
Neurosurg Psychiatry (2002) 72:608–14. doi:10.1136/jnnp.72.5.608 
47. Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, et al. 
Factors affecting the health-related quality of life of patients with cervical 
dystonia and the impact of botulinum toxin type A injections. Funct Neurol 
(2007) 22:95–100. 
48. Avanzino L, Martino D, Marchese R, Aniello MS, Minafra B, Superbo M, et al. 
Quality of sleep in primary focal dystonia: a case-control study. Eur J Neurol 
(2010) 17:576–81. doi:10.1111/j.1468-1331.2009.02884.x 
49. Paus S, Gross J, Moll-Muller M, Hentschel F, Spottke A, Wabbels B, et  al. 
Impaired sleep quality and restless legs syndrome in idiopathic focal 
dystonia: a controlled study. J Neurol (2011) 258:1835–40. doi:10.1007/
s00415-011-6029-6 
50. Eichenseer SR, Stebbins GT, Comella CL. Beyond a motor disorder: a prospec-
tive evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord 
(2014) 20:405–8. doi:10.1016/j.parkreldis.2014.01.004 
51. Trotti LM, Esper CD, Feustel PJ, Bliwise DL, Factor SA. Excessive daytime 
sleepiness in cervical dystonia. Parkinsonism Relat Disord (2009) 15:784–6. 
doi:10.1016/j.parkreldis.2009.04.007 
52. Romano R, Bertolino A, Gigante A, Martino D, Livrea P, Defazio G. 
Impaired cognitive functions in adult-onset primary cranial cervical 
dystonia. Parkinsonism Relat Disord (2014) 20:162–5. doi:10.1016/ 
j.parkreldis.2013.10.008 
53. Hinse P, Leplow B, Humbert T, Lamparter U, Junge A, Emskotter T. Impairment 
of visuospatial function in idiopathic spasmodic torticollis. J Neurol (1996) 
243:29–33. doi:10.1007/BF00878528 
54. Allam N, Frank JE, Pereira C, Tomaz C. Sustained attention in cranial dystonia 
patients treated with botulinum toxin. Acta Neurol Scand (2007) 116:196–200. 
doi:10.1111/j.1600-0404.2007.00862.x 
55. Conte A, Berardelli I, Ferrazzano G, Pasquini M, Berardelli A, Fabbrini 
G. Non-motor symptoms in patients with adult-onset focal dystonia: 
sensory and psychiatric disturbances. Parkinsonism Relat Disord (2016) 
22(Suppl 1):S111–4. doi:10.1016/j.parkreldis.2015.09.001 
56. Hutchinson M, Kimmich O, Molloy A, Whelan R, Molloy F, Lynch T, et al.  
The endophenotype and the phenotype: temporal discrimination and 
adult-onset dystonia. Mov Disord (2013) 28:1766–74. doi:10.1002/mds. 
25676 
57. Jinnah HA, Berardelli A, Comella C, Defazio G, Delong MR, Factor S, et al. 
The focal dystonias: current views and challenges for future research. Mov 
Disord (2013) 28:926–43. doi:10.1002/mds.25567 
58. Fuchs T, Saunders-Pullman R, Masuho I, Luciano MS, Raymond D, Factor S, 
et al. Mutations in GNAL cause primary torsion dystonia. Nat Genet (2013) 
45:88–92. doi:10.1038/ng.2496 
59. Vemula SR, Puschmann A, Xiao J, Zhao Y, Rudzinska M, Frei KP, et al. Role of 
Galpha(olf) in familial and sporadic adult-onset primary dystonia. Hum Mol 
Genet (2013) 22:2510–9. doi:10.1093/hmg/ddt102 
60. Charlesworth G, Plagnol V, Holmstrom KM, Bras J, Sheerin UM, Preza E, 
et  al. Mutations in ANO3 cause dominant craniocervical dystonia: ion 
channel implicated in pathogenesis. Am J Hum Genet (2012) 91:1041–50. 
doi:10.1016/j.ajhg.2012.10.024 
61. Delnooz C, MWIM H, MA T, van de Warrenburg BP. Paramedical treat-
ment in primary dystonia: a systematic review. Movement Disorders (2009) 
24:2187–98. doi:10.1002/mds.22608 
62. De Pauw J, Van der Velden K, Meirte J, Van Daele U, Truijen S, Cras P, et al. 
The effectiveness of physiotherapy for cervical dystonia: a systematic literature 
review. J Neurol (2014) 261:1857–65. doi:10.1007/s00415-013-7220-8 
63. Tassorelli C, Mancini F, Balloni L, Pacchetti C, Sandrini G, Nappi G, et  al. 
Botulinum toxin and neuromotor rehabilitation: an integrated approach to 
idiopathic cervical dystonia. Mov Disord (2006) 21:2240–3. doi:10.1002/
mds.21145 
64. El-Bahrawy M, El-Tamawy M, Shalaby N, Abdelalim A. Cervical dystonia: 
abnormal head posture and its relation to hand function. Egypt J Neurol 
Psychiat Neurosurg (2009) 46:203–8. 
65. Boyce MJ, Canning CG, Mahant N, Morris J, Latimer J, Fung VS. Active 
exercise for individuals with cervical dystonia: a pilot randomized controlled 
trial. Clin Rehabil (2013) 27:226–35. doi:10.1177/0269215512456221 
66. Queiroz MA, Chien HF, Sekeff-Sallem FA, Barbosa ER. Physical therapy 
program for cervical dystonia: a study of 20 cases. Funct Neurol (2012) 27: 
187–92. 
67. Bleton JP. Physiotherapy of focal dystonia: a physiotherapist’s personal 
experience. Eur J Neurol (2010) 17:107–12. doi:10.1111/j.1468-1331.2010. 
03061.x 
68. Dool JVD, Visser B, Koelman JHTM, Engelbert RHH, Tijssen MAJ. Cervical 
dystonia: effectiveness of a standardized physical therapy program; study 
design and protocol of a single blind randomized controlled trial. Movement 
Disorders (2013) 28(Suppl 1): S1–511.
69. Quartarone A, Rizzo V, Morgante F. Clinical features of dystonia: a patho-
physiological revisitation. Curr Opin Neurol (2008) 21:484–90. doi:10.1097/
WCO.0b013e328307bf07 
70. Kleim JA, Jones TA. Principles of experience-dependent neural plasticity: 
Implications for rehabilitation after brain damage. J Speech Language Hearing 
Res (2008) 51:S225–39. doi:10.1044/1092-4388(2008/018) 
71. Schmidt RA, Lee TD. Motor Control and Learning: A Behavioral Emphasis. 
Champaign, IL: Human Kinetics (1999).
72. Shea CH, Shebilske WL, Worchel S. Motor Learning and Control. Englewood 
Cliffs, NJ: Prentice-Hall (1993).
73. Shea JB, Morgan RL. Contextual interference effects on the acquisition, reten-
tion, and transfer of a motor skill. J Exp Psychol Human Learning Memory 
(1979) 5:179–87. doi:10.1037/0278-7393.5.2.179 
74. Bleton JP, Vidailhet M, Bourdain F, Ducorps A, Schwartz D, Delmaire C, et al. 
Somatosensory cortical remodelling after rehabilitation and clinical benefit of 
in writer’s cramp. J Neurol Neurosurg Psychiatry (2011) 82:574–7. doi:10.1136/
jnnp.2009.192476 
7Contarino et al. Unmet Needs in the Management of Cervical Dystonia
Frontiers in Neurology | www.frontiersin.org September 2016 | Volume 7 | Article 165
Conflict of Interest Statement: MC, Advisory board: Medtronic, Boston Scientific., 
is co-inventor on a patent application relevant to Deep Brain Stimulation (2014). 
Speaking fees: Abbvie, Medtronic, Boston Scientific, ECMT. Grant: Stichting 
Parkinson Fonds. MS: Grants: University Medical Centre Groningen, Stichting 
Wetenschapsfonds Dystonie Vereniging. JD: Grants: Dutch organizations in 
scientific research, the Fonds Nutsohra, Jacques and Gloria Gossweiler foundation 
and Stichting Wetenschapsfonds Dystonie Vereniging. JV: advisory boards: Boston 
Scientific, Medtronic; grant support: Boston Scientific, Medtronic; Speaking fees: 
Boston Scientific, Medtronic, St. Jude, UCB, TEVA, and Allergan. MT: Grants: 
Netherlands organization for scientific research-NWO, Medium, Fonds Nuts-Ohra, 
Prinses Beatrix Fonds, Gossweiler foundation, Stichting wetenschapsfonds dys-
tonie vereniging, Phelps Stichting, educational grants and national DystonieNet 
grants from Ipsen and Allergan Famaceutics, Merz, Medtronic and Actelion.
Copyright © 2016 Contarino, Smit, van den Dool, Volkmann and Tijssen. This is an 
open-access article distributed under the terms of the Creative Commons Attribution 
License (CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
